These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 11821958

  • 21. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.
    Cancer Res; 2000 Jun 01; 60(11):3081-7. PubMed ID: 10850460
    [Abstract] [Full Text] [Related]

  • 22. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach.
    French JD, Tschumper RC, Jelinek DF.
    Leukemia; 2002 Jun 01; 16(6):1189-96. PubMed ID: 12040452
    [Abstract] [Full Text] [Related]

  • 23. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor.
    Lin SK, Kok SH, Yeh FT, Kuo MY, Lin CC, Wang CC, Goldring SR, Hong CY.
    Arthritis Rheum; 2004 Mar 01; 50(3):785-93. PubMed ID: 15022320
    [Abstract] [Full Text] [Related]

  • 24. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D.
    Cancer Res; 2006 Apr 01; 66(7):3903-11. PubMed ID: 16585219
    [Abstract] [Full Text] [Related]

  • 25. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.
    Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH, Lee AV.
    Cancer Res; 2006 May 15; 66(10):5304-13. PubMed ID: 16707456
    [Abstract] [Full Text] [Related]

  • 26. Oncostatin M suppresses EGF-mediated protein tyrosine phosphorylation in breast cancer cells.
    Spence MJ, Vestal RE, Ma Y, Streiff R, Liu J.
    Cytokine; 2000 Jul 15; 12(7):922-33. PubMed ID: 10880237
    [Abstract] [Full Text] [Related]

  • 27. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
    Halfter H, Postert C, Friedrich M, Ringelstein EB, Stögbauer F.
    Brain Res Mol Brain Res; 2000 Sep 15; 80(2):198-206. PubMed ID: 11038252
    [Abstract] [Full Text] [Related]

  • 28. Cell density-dependent regulation of hepatic development by a gp130-independent pathway.
    Kojima N, Kinoshita T, Kamiya A, Nakamura K, Nakashima K, Taga T, Miyajima A.
    Biochem Biophys Res Commun; 2000 Oct 14; 277(1):152-8. PubMed ID: 11027656
    [Abstract] [Full Text] [Related]

  • 29. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.
    Mol Cancer Res; 2009 Feb 14; 7(2):275-84. PubMed ID: 19208749
    [Abstract] [Full Text] [Related]

  • 30. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.
    Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP, Ethier SP.
    Oncogene; 2005 Apr 28; 24(19):3177-86. PubMed ID: 15735691
    [Abstract] [Full Text] [Related]

  • 31. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
    Zhang T, Ma J, Cao X.
    Biochem J; 2003 Dec 01; 376(Pt 2):457-64. PubMed ID: 14498832
    [Abstract] [Full Text] [Related]

  • 32. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
    Huang L, Watanabe M, Chikamori M, Kido Y, Yamamoto T, Shibuya M, Gotoh N, Tsuchida N.
    Oncogene; 2006 Oct 19; 25(49):6457-66. PubMed ID: 16702953
    [Abstract] [Full Text] [Related]

  • 33. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 34. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
    Song L, Turkson J, Karras JG, Jove R, Haura EB.
    Oncogene; 2003 Jul 03; 22(27):4150-65. PubMed ID: 12833138
    [Abstract] [Full Text] [Related]

  • 35. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells.
    Nagata T, Kai H, Shibata R, Koga M, Yoshimura A, Imaizumi T.
    Arterioscler Thromb Vasc Biol; 2003 Apr 01; 23(4):588-93. PubMed ID: 12615664
    [Abstract] [Full Text] [Related]

  • 36. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
    Tari AM, Hung MC, Li K, Lopez-Berestein G.
    Oncogene; 1999 Feb 11; 18(6):1325-32. PubMed ID: 10022814
    [Abstract] [Full Text] [Related]

  • 37. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
    Alper O, Hacker NF, Cho-Chung YS.
    Oncogene; 1999 Sep 02; 18(35):4999-5004. PubMed ID: 10490835
    [Abstract] [Full Text] [Related]

  • 38. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
    Ram TG, Schelling ME, Hosick HL.
    Cell Growth Differ; 2000 Mar 02; 11(3):173-83. PubMed ID: 10768865
    [Abstract] [Full Text] [Related]

  • 39. Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells.
    Palmer J, Hertzog PJ, Hammacher A.
    Int J Biochem Cell Biol; 2004 Nov 02; 36(11):2258-69. PubMed ID: 15313471
    [Abstract] [Full Text] [Related]

  • 40. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
    Mol Cancer Res; 2007 Apr 02; 5(4):393-401. PubMed ID: 17426253
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.